Search results
Results From The WOW.Com Content Network
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cassava Sciences wasn’t one of them. The 10 stocks that made ...
Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.
"This controversy could be a significant long-term challenge to realizing upside in Cassava stock", Bernardino said. Doubts concerning the drug emerged three years ago and was followed by an ...
The stock tumbled over 20% following a fireside chat, where CEO Remi Barbier outlined the progress being made in bringing simufilam, Cassava’s controversial Alzheimer’s drug candidate, to ...
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
Shares of Cassava are moving higher on news that its rival Roche suffered a setback in its Alzheimer's drug research trial.